Conventional detection of advanced fatty liver disease relies on biopsy. Less onerous methods may help to save lives.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Loomba, R. et al. Hepatology 61, 1239–1250 (2015).
Loomba, R. et al. Cell Metab. 25, 1054–1062 (2017).
Ginès, P. et al. Lancet Gastroenterol. Hepatol. 1, 256–260 (2016).
Caussy, C. et al. J. Clin. Invest. 127, 2697–2704 (2017).
Additional information
This article is part of Nature Outlook: Fatty liver disease, an editorially independent supplement produced with the financial support of third parties. About this content.
Rights and permissions
About this article
Cite this article
Eisenstein, M. Diagnostics: Missing the point. Nature 551, S90–S91 (2017). https://doi.org/10.1038/d41586-017-06048-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/d41586-017-06048-8